Completed – Kidney Health Initiative (KHI)

Xenotransplantation: Patient FAQ

Xenotransplantation: Patient FAQ Projects Portfolio: Insert Portfolio Barrier Type: Insert Barrier Type This project is a collaboration between the National Kidney Foundation (NKF), Kidney Health Initiative, and the Food

Developing a Roadmap to Accelerate the Expansion of AKI Biomarkers for Drug Development

Developing a Roadmap to Accelerate the Expansion of AKI Biomarkers for Drug Development Projects Portfolio: Drugs Barrier Type: Clinical Trial Endpoints Biomarkers—objective, measurable characteristics of biological processes—are critical to assess

Surrogate Endpoints in FSGS

Despite being associated with a relatively rapid decline in kidney function, there are no approved drugs and no accepted endpoints for registration of investigational products for FSGS.

Patient-Reported Outcome Measures for Novel Renal Devices

Attention to the innovation deficit in treatments for kidney failure is increasing. As development of next generate kidney replacement therapy begins to accelerate, the perspectives of people with kidney failure must not be overlooked.

Patient Reported Outcomes for Muscle Cramping

Muscle cramping is an especially bothersome symptom in patients receiving dialysis, regardless of modality.

Patient Advisory Boards

To further patient input in KHI, the Patient and Family Partnership Council (PFPC) partners with KHI Board of Directors (BOD) to advise and make recommendations on KHI member efforts so that the patient’s voice, experience, and involvement is meaningful and effective in biomedical research and product development.

Xenotransplantation: Patient FAQ

Developing a Roadmap to Accelerate the Expansion of AKI Biomarkers for Drug Development

Surrogate Endpoints in FSGS

Patient-Reported Outcome Measures for Novel Renal Devices

Patient Reported Outcomes for Muscle Cramping

Patient Advisory Boards

Involving Kidney Patients in Cardiovascular Trials

Incorporating Patient Preferences in the Development of Novel Kidney Replacement Therapy

Endpoints for Hyperoxaluria Clinical Trials

Endpoints for C3 Glomerulopathy (C3G)